language_icon
EN
HI

Onesource Specialty Pharma Share price

ONESOURCE

1773.9

10.90 (0.62%)
NSE
BSE
Last updated on 29 Apr, 2026 | 14:11 IST
Today's High

1840.00

Today's Low

1768.10

52 Week Low

1057.00

52 Week High

2248.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Onesource Specialty Pharma Chart

Onesource Specialty Pharma Share Key Metrics

Volume
5.42 L
Market Cap
20207.72 CR
LTQ@LTP
1@1773.90
ATP
1809.55
Var Margin
21.9 %
Circuit Range
1410.4-2115.6
Delivery %
36.73 %
Value
98.14 CR
ASM/GSM
No
Market Lot
1

Summary

Onesource Specialty Pharma share price stands at ₹1773.9 at 29 Apr, 2026 | 14:11. The stock Onesource Specialty Pharma intraday movement has stayed between ₹1768.10 and ₹1840.00, while on a 52-week basis it has fluctuated from ₹1057.00 to ₹2248.00.
In terms of trading activity, Onesource Specialty Pharma has recorded a volume of 542326 shares. The Onesource Specialty Pharma has a market cap of ₹114621201. The stock’s Average Traded Price (ATP) stands at ₹180955, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1, 177390.
The Onesource Specialty Pharma operates within a circuit range of ₹1410.4-2115.6 – ₹1410.4-2115.6, with a Value of ₹98.14 CR. The Delivery Percentage for the day is 36.73%. Additionally, Onesource Specialty Pharma currently falls under the No framework, and trades with a market lot size of 1.

Onesource Specialty Pharma Fundamentals

View More
P/E Ratio

1005.16

P/B Ratio

3.47

Div. Yield

0

Sector P/E

64.46

Sector P/B

3.52

Sec. Div. Yield

0.57

Onesource Specialty Pharma Resistance and Support

Pivot 1781.3

Resistance

First Resistance

1817.6

Second Resistance

1872.2

Third Resistance

1908.5

Support

First Support

1726.7

Second Support

1690.4

Third Support

1635.8

Onesource Specialty Pharma Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

30.48%

Mutual Fund

10.13%

Insurance

3.35%

Foreign Institutional Investors

17.5%

Domestic Institutional Investors

7.13%

Retail

31.41%

Others

0%

Total Promoters
MAR '26
30.48%

Onesource Specialty Pharma Corporate Actions

DateAgenda
2026-01-23Quarterly Results
2025-11-11Quarterly Results
2025-08-04Quarterly Results
2025-05-05Audited Results

Onesource Specialty Pharma News

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Onesource's partner, Dr. Reddy's Laboratories, received Health Canada approval for generic Semaglutide Injection. Onesource will serve as the CDMO partner for scale-up and commercial manufacturing from its US-FDA approved facility in Bengaluru.
Apr 29 2026 09:04:00

Onesource Specialty Pharma Limited

OneSource's Sterile Product Division in Bangalore received an EU GMP Certificate from German authorities. This certification confirms compliance with EU GMP requirements for sterile products, ensuring quality for small volume liquids and testing.
Apr 28 2026 21:04:00

Onesource Specialty Pharma shares gain after equity worth ₹408 crore changes hands in block deals

Onesource Specialty Pharma's partner has received USFDA approval for a generic version of Ozempic, a development that is expected to create new contract manufacturing opportunities for Onesource, impacting its contract development and manufacturing organization (CDMO) services positively.
Apr 21 2026 11:04:00

Onesource Specialty Pharma partner wins tentative USFDA nod for generic Ozempic; Stock falls

OneSource Specialty Pharma has received regulatory approval from Saudi Arabia for its generic version of Ozempic (semaglutide) and will commercialize it with its partner Hikma Pharmaceuticals in the Middle East and North Africa region, leveraging a significant growth opportunity in the GLP-1 market.
Apr 21 2026 09:04:00

Onesource Specialty Pharma Limited

OneSource's partner Orbicular secured tentative U.S. FDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, providing end-to-end manufacturing capabilities. This reinforces OneSource's position in complex pharmaceutical products.
Apr 21 2026 08:04:00

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

OneSource Specialty Pharma's partner Orbicular secured tentative U.S. FDA ANDA approval for generic Ozempic® (Semaglutide Injection). OneSource acted as the CDMO partner, utilizing its US-FDA approved manufacturing site in Bangalore for production.
Apr 21 2026 08:04:00

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Ltd successfully renewed its EU-GMP certification for its Bengaluru Unit II manufacturing facility. This certification validates the facility's capabilities in integrated biologics drug-substance and drug-product manufacturing, including sterile injectable products, following an inspection by a European regulatory authority.
Apr 17 2026 19:04:00

Onesource Specialty Pharma Ltd - 544292 - Intimation Of "Renewal Of EU -GMP Certification For Onesource : Flagship Unit II Facility

OneSource Specialty Pharma Ltd secured the renewal of its EU-GMP certification for its Flagship Unit II manufacturing facility in Bengaluru. This certification ensures continued compliance for its integrated biologics drug-substance and drug-product manufacturing site.
Apr 17 2026 19:04:00

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited received an independent ESG rating of '73' (Leader category) from NSE Sustainability for FY25. The rating was based on publicly available information and not through direct company engagement.
Apr 16 2026 10:04:00

Onesource Specialty Pharma Ltd - 544292 - Intimation Of ESG Rating

OneSource Specialty Pharma Limited received an independent ESG rating of '73' (Leader category) from NSE Sustainability for FY25. The rating was independently assigned based on publicly available information.
Apr 16 2026 10:04:00
Read More

About Onesource Specialty Pharma

NSE : 29224  
BSE : 544292  
ISIN : INE013P01021  

Onesource Specialty Pharma Management

NamePosition
A TrishaCompany Secretary & Compliance Officer
Arun KumarChairman
View More

Onesource Specialty Pharma FAQs

The Buying Price of Onesource Specialty Pharma share is 1773.9 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Onesource Specialty Pharma stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Onesource Specialty Pharma, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Onesource Specialty Pharma shares is 1005.16. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Onesource Specialty Pharma shares is 3.47. Useful to assess the stock's value relative to its book value.

To assess Onesource Specialty Pharma’s valuation compare Sector P/E, P/B which are 64.46 & 3.52 with sector averages, along with growth rates and financial metrics.

The Market Cap of Onesource Specialty Pharma is 20207.72 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Onesource Specialty Pharma share price is 2248.00 & 1057.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Onesource Specialty Pharma belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost